Your browser doesn't support javascript.
loading
Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
Nishiyama, Ayae; Adachi, Yu; Tonouchi, Keisuke; Moriyama, Saya; Sun, Lin; Aoki, Masamitsu; Asanuma, Hideki; Shirakura, Masayuki; Fukushima, Akihisa; Yamamoto, Takuya; Takahashi, Yoshimasa.
Afiliación
  • Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6
  • Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan.
  • Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan; Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsucho Shinjuku, Tokyo 162-8480, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan.
  • Sun L; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan.
  • Aoki M; Sumitomo Pharma. Co., Ltd., 3-1-98, Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
  • Asanuma H; Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama-shi, Tokyo 208-0011, Japan.
  • Shirakura M; Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama-shi, Tokyo 208-0011, Japan.
  • Fukushima A; Sumitomo Pharma. Co., Ltd., 3-1-98, Kasugade-naka, Konohana-ku, Osaka 554-0022, Japan.
  • Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8, Saito-Asagi, Ibaraki City, Osaka 567-0085, Japan; Laboratory of Aging and Immune Regulation, Graduate School of Pharmaceutical Sciences,
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku, Tokyo 162-8640, Japan. Electronic address: ytakahas@niid.go.jp.
Vaccine ; 41(31): 4525-4533, 2023 07 12.
Article en En | MEDLINE | ID: mdl-37330368
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Infecciones por Orthomyxoviridae / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Infecciones por Orthomyxoviridae / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article